<DOC>
	<DOCNO>NCT02806947</DOCNO>
	<brief_summary>The study Phase II randomize , open label , multicenter trial design identify whether sirolimus potential alternative prednisone up-front treatment patient standard-risk acute GVHD define accord clinical biomarker-based risk stratification . This trial incorporate novel front GVHD therapy ( sirolimus ) well novel BMT CTN develop acute GVHD biomarker test .</brief_summary>
	<brief_title>A Study Evaluate Steroid-free Treatment Standard-Risk aGVHD ( BMT CTN 1501 )</brief_title>
	<detailed_description>The study Phase II randomize , open label , multicenter trial design identify whether sirolimus potential alternative prednisone up-front treatment patient standard-risk acute GVHD define accord clinical biomarker-based risk stratification . Patients previously untreated , standard-risk acute GVHD , accord refine Minnesota Criteria , need systemic therapy , 5 mL blood sample collect prior randomization ass biomarker Ann Arbor Risk status . Ann Arbor score result provide 48-72 hour randomization . Patients begin study treatment assignment within 24 hour randomization . Those biomarker result combine AA1/2 risk continue randomize study treatment include primary endpoint analysis ( Day 28 complete partial response ) plan study procedure assessment . In contrast , patient AA3 biomarker risk patient miss biomarker result may continue randomized therapy start another therapy physicians ' discretion . In addition , AA3 risk patient miss result consider primary endpoint analysis , include subset analysis .</detailed_description>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1 . Patients standardrisk acute GVHD , accord refine Minnesota Criteria . Refined Minnesota Criteria available http : //redcap.ahc.umn.edu/surveys/ ? s=bNmFhseJIf . Standardrisk acute GVHD accord refine Minnesota Risk Criteria require meet one criterion : 1 . Single organ involvement ( Stage 13 skin , Stage 1 upper GI , Stage 12 low GI ) 2 . Multiple organ involvement ( Stage 13 skin plus stage 1 upper GI , Stage 13 skin plus stage 1 low GI , Stage 13 skin plus stage 1 low GI plus stage 1 upper GI , Stage 13 skin plus stage 14 liver , Stage 1 low GI plus stage 1 upper GI ) 2 . Acute Minnesota Standard Risk GVHD require systemic immune suppressive therapy . 3 . Acute GVHD develop allogeneic hematopoietic cell transplantation use either bone marrow , peripheral blood , umbilical cord blood . Recipients nonmyeloablative , reduced intensity condition myeloablative transplant eligible . All allogeneic donor source permit , include sibling , unrelated donor , human leukocyte antigen ( HLA ) haploidentical related donor umbilical cord blood . 4 . Patients NOT receive systemic immune suppressive therapy treatment active GVHD ( topical skin GI corticosteroid allow ) . 5 . Ability tolerate oral entericallyadministered medication . 6 . Patients age . 7 . Absolute neutrophil count ( ANC ) great 500/ÂµL . 8 . Biopsy confirmation GVHD require . Enrollment delay biopsy pathology result unless local institutional practice mandate biopsy confirmation make GVHD treatment decision . 9 . Written inform consent and/or assent patient , parent guardian . 10 . Collection 5 ml blood sample ( red top serum ) patient Ann Arbor Scoring ready ship immediately randomization . 1 . Patients receive sirolimus ( indication include GVHD prophylaxis ) within 14 day screen enrollment . 2 . Relapsed , progress persistent malignancy require withdrawal systemic immune suppression . 3 . Patients acute GVHD develop donor lymphocyte infusion . 4 . Active recent ( within 7 day ) episode transplant associate microangiopathy . 5 . Patients uncontrolled infection exclude . Infections consider controlled appropriate therapy institute , time enrollment , sign progression present . Progression infection define hemodynamic instability attributable sepsis , new symptom , worsen physical sign radiographic finding attributable infection . Persisting fever without sign symptom interpret progress infection . 6 . Patients unlikely available evaluation transplant center Day 28 56 therapy . 7 . A clinical presentation resemble de novo chronic GVHD overlap syndrome develop present time enrollment . 8 . Patients receive corticosteroid indication within 7 day onset acute GVHD , except follow : Stable replacement dos corticosteroids adrenal insufficiency permit ( e.g . hydrocortisone total dose 1012 mg/m^2/day prednisone 57.5mg daily equivalent ) . Corticosteroids administer premedication transfusion blood product intravenous medication prevent infusion reaction allow . 9 . Patients pregnant breastfeeding . 10 . Females childbearing potential ( FCBP ) man sexual contact FCBP unwilling use effective birth control duration study . 11 . Patients dialysis . 12 . Patients mechanical ventilation . 13 . Patients severe hepatic sinusoidal obstruction syndrome judgment treat physician expect normalized bilirubin Day 56 enrollment . 14 . Patients history hypersensitivity sirolimus component formulation .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Acute GVHD</keyword>
	<keyword>Standard-Risk</keyword>
	<keyword>Sirolimus</keyword>
	<keyword>Refined Minnesota Risk Criteria</keyword>
	<keyword>Ann Arbor</keyword>
	<keyword>Biomarker</keyword>
	<keyword>Steroid-Free</keyword>
</DOC>